Fundraising Fox
/Companies
Sign in

JUMPCODE Genomics

San Diego, US · Founded 2016 · Delaware corporation · 7 employees on LinkedIn · 4 known investors

Find your way into JUMPCODE Genomics

Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.

AI & Machine LearningBiotechDeep TechHealthtech

Founders & leadership

DM
David Michael SalterExecutive
MSMike Salter
Mike SalterCEO/President
EC
Eugene ChenNamed on SEC filing
KB
Keith BrownNamed on SEC filing
JR
Joel RotroffNamed on SEC filing

Board

CT
Court TurnerBoard directorPartner at LYZZ Capital
JL
Joseph LeeBoard director
KMKirk Malloy
Kirk MalloyBoard directorPhD at Arboretum Ventures

Investors · 4

Baird Capitallisted by Baird CapitalChicago

How we know: Baird Capital's portfolio page · Not right? Tell us

Global Health Investment Corporationlisted by Global Health Investment CorporationNew York

How we know: Global Health Investment Corporation's portfolio page · Not right? Tell us

LYZZ Capitallisted by LYZZ CapitalShanghai

Reported raises · per SEC filings

Form D private placements

$38.7M disclosed across 5 rounds · 2018–2024

▶$3.5MraisedAug 2024 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David Michael SalterExecutive Officer, Director
  • Court TurnerDirector
  • Joseph LeeDirector
Offering amount
$11.5M
Amount sold
$3.5M
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.2MraisedMay 2023 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yaron HakakExecutive Officer, Director
  • Frank WitneyDirector
  • Court TurnerDirector
  • Kirk MalloyDirector
  • Dan KidleDirector
  • Brandon PoeExecutive Officer
Offering amount
$16.1M
Amount sold
$9.2M
First sale
Apr 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21MraisedDec 2020 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith BrownExecutive Officer
  • Yaron HakakExecutive Officer, Director
  • Dan KidleDirector
  • Kirk MalloyDirector
  • Kevin LiDirector
  • Frank WitneyDirector
  • Michael LiangDirector
Offering amount
$21M
Amount sold
$21M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith BrownExecutive Officer, Director
  • Eugene ChenDirector
  • Kevin LiDirector
  • Joel RotroffDirector
  • Kirk MalloyDirector
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Jan 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedSep 2018 · 4 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eugene ChenDirector
  • Keith BrownExecutive Officer, Director
  • Joel RotroffDirector
  • Kirk MalloyDirector
Offering amount
$3.5M
Amount sold
$3.5M
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Oup11 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
IDbyDNA10 shared keywordsScalable, high throughput DNA sequencing platforms.
Transcode Therapeutics6 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
10x Genomics 1-color6 shared keywords10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.

Companies competing with JUMPCODE Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does JUMPCODE Genomics do?
Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers. Its technology is used in basic research, infectious disease, oncology, and consumer genomics.
Who are JUMPCODE Genomics's investors?
JUMPCODE Genomics's investors include Arboretum Ventures, Baird Capital, Global Health Investment Corporation, LYZZ Capital.
How much funding has JUMPCODE Genomics raised?
JUMPCODE Genomics has disclosed $38.7M raised across 5 rounds.
Where is JUMPCODE Genomics headquartered?
JUMPCODE Genomics is headquartered in San Diego, US.